WHEATON has announced the appointment of Wayne Brinster to the role of president, succeeding Stephen R, Drozdow, who remains as chief executive officer.
Mr. Brinster brings to the position a familiar, science-driven focus while sharing Mr. Drozdow’s long-time commitment to WHEATON customers, suppliers, partners and employees.
Mr. Brinster comes to WHEATON from Synthon Pharmaceuticals, a privately owned manufacturer of pharmaceutical and biopharmaceutical products, where he served as vice president and general manager.
Prior to Synthon, Mr. Brinster worked in different management roles for over 30 years at Becton, Dickinson and Company, where he most recently led the BD Diagnostics Women’s Health and Cancer Care initiative.
“Having spent most of my life in the business of science, I am excited to be here with a leading name in the field, joining an organization that has developed a reputation for supporting important scientific achievements,” said Mr. Brinster.
“By leveraging technical knowledge with excellent customer service, we’re going to continue placing WHEATON at the forefront of the industry,” he added.
Mr. Drozdow, after leading WHEATON since 1996, will become the chief executive officer and will continue to have an active role at WHEATON, working closely with Mr. Brinster on matters pertaining to strategy, key industry relationships, finance, budgets and acquisitions. “Wayne is a great business leader,” said Mr. Drozdow. “He understands the science of our markets, knows our industry and identifies with our approach to customers.”